Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient?

Basit Öğe Kaydı
dc.authoridayhan, murat/0000-0002-0631-4006
dc.authoridOzcelik, Serhat/0000-0002-0521-5866
dc.authoridOzcelik, Melike/0000-0003-0406-715X
dc.authorwosidAy, Murat/GSI-4353-2022
dc.contributor.authorOzyurt, Esra
dc.contributor.authorOzcelik, Serhat
dc.contributor.authorSurmeli, Heves
dc.contributor.authorCelik, Mehmet
dc.contributor.authorAyhan, Murat
dc.contributor.authorOzcelik, Melike
dc.date.accessioned2024-06-12T11:09:14Z
dc.date.available2024-06-12T11:09:14Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction Nivolumab is a human immunoglobulin G4 monoclonal antibody that inhibits programmed cell death-1 activity by binding to the programmed cell death-1 receptors. Cancer cells express increased number of programmed cell death-1 ligands and this allows them to escape the cytotoxic effects of the T cells. Therefore, the negative programmed cell death-1 receptor signal regulates T-cell proliferation and activation is disrupted. However, this change in the activity of the T cells can cause them to lose their ability to recognize host cells. The immune response enabled by these agents has led to side effects, commonly known as immune-related adverse events. Case report We report a case of a 66-year-old male patient who was treated with nivolumab for recurrent renal cell carcinoma presented with hepatitis and adrenalitis. Three weeks after starting nivolumab, the patient had abdominal pain and weakness, and then aspartate and alanine transaminase levels were found to be elevated. Management and outcome Hepatitis was predicted to be due to nivolumab, because other causes were excluded. He started using oral methylprednisolone and then, hepatitis improved. However, while receiving methylprednisolone treatment, fludrocortisone was started with the pre-diagnosis of adrenalitis due to the persistence of fatigue, weakness, and hyponatremia and hyperkalemia. With both treatments, the patient's symptoms and sodium and potassium level returned to normal. Discussion This case emphasizes the need for patient's education and awareness of immune-related adverse events, and the importance of understanding the management of life-threatening complications of the checkpoint inhibitors, because these side effects require prompt recognition and treatment.en_US
dc.identifier.doi10.1177/10781552211038136
dc.identifier.endpage465en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue2en_US
dc.identifier.pmid34558355en_US
dc.identifier.scopus2-s2.0-85115689171en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage462en_US
dc.identifier.urihttps://doi.org/10.1177/10781552211038136
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22733
dc.identifier.volume28en_US
dc.identifier.wosWOS:000702392700001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal Of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNivolumaben_US
dc.subjectImmune Checkpoint Inhibitoren_US
dc.subjectAdrenalitisen_US
dc.subjectNivolumaben_US
dc.subjectManagementen_US
dc.titleSide effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu